Galon et al., investigated CD3+ T cells and CD8+ CTLs in the center of a tumor and at the invasive margin, and reported the immunological data as a more robust survival predictor than the histopathological methods in clinical practice to segregate between CRC stages [14]. The gene discussed is CD8A; the disease is neoplasm.